Keros Plummets 73% After Unexpected Side Effects 'Shock' Its Lead Drug
Keros Therapeutics stock plummeted Thursday after the company stopped giving higher doses in a lung disease study due to side effects.
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
Keros Therapeutics stock plummeted Thursday after the company stopped giving higher doses in a lung disease study due to side effects.